A randomised, double-blind, dose finding study of inhaled alginate oligosaccharide (OligoG) vs placebo in patients with Cystic Fibrosis (CF).

AlgiPharma AS0 sites168 target enrollmentJuly 5, 2019

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

July 5, 2019

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

AlgiPharma AS

Eligibility Criteria

Inclusion Criteria

•Confirmed diagnosis of Cystic Fibrosis (CF) defined as a sweat chloride value \=60 mmol/L by quantitative pilocarpine iontophoresis or genotypic confirmation of CFTR mutation.
•Age 12 years or older.
•Male or female patients with any ethnicity.
•FEV1 at screening in the range of \=40% and \= 90% of the predicted normal for age, sex, and height, according to the GLI equation (Eur Respir J. Dec 2012; 40(6\): 1324–1343\).
•A documented history of chronic Pseudomonas aeruginosa (PA)
•History of antibiotic treatment due to PA infection (not for eradication therapy) during the last 12 months
•Concomitant treatment with inhaled tobramycin, colistin, aztreonam or levofloxacin (either cycled or continuous) for at least 3 months at screening to treat PA infection. In case of cycled inhaled antibiotic treatment, randomisation should be done at the start of a new cycle \+/\- 2 days.
•(together with the IMP intake).days.
•Stable CF disease as judged by the investigator.
•Willing to remain on a stable CF medication regimen (standard of care; SOC) during the study.

Exclusion Criteria

•Use of hypertonic saline more than 2 times a day. If hypertonic saline is used, IMP inhalation should be taken 15 minutes after completion of hypertonic saline therapy.
•Use of CFTR modulator therapies.
•Clinically significant abnormal findings or any value \> 3x the upper normal limit of haematology or clinical chemistry parameters, except for the inflammation marker C\-reactive protein (CRP), as CRP is standardly increased in CF patients. Further exceptions may be allowed in the case of elevated gamma\-GT (GGT) values, exceeding this threshold. These GGT cases will be carefully scrutinised alongside other clinical and laboratory data. Following discussion between the medical monitor and the principal investigator to exclude significant liver injury, the subject may be enrolled in the study.
•History of any comorbidity that, in the opinion of the investigator, might distort the results of the study or cause an additional risk in administering study drug to the patient.
•Pulmonary exacerbation within 28 days prior to randomisation.
•Change in CF therapy within 28 days before randomisation (first dose of IMP).
•Pregnant or breastfeeding females.
•Hypersensitivity (allergic reaction of any grade) to the IMP or to any of the excipients or placebo.
•Patients unable to perform pulmonary function tests according to the ATS/ERS criteria.
•Uncontrolled or unstable acute or chronic diseases (e.g. congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations) that would limit the compliance with study requirements in the opinion of the investigator.